CAR-T 细胞免疫疗法的临床应用与进展
| 作者: |
1邹露,
1李丽敏,
1孟红彬,
1周晋
1 哈尔滨医科大学附属第一医院血液内科，哈尔滨 150001 |
| 通讯: |
周晋
Email: zhoujin1111@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.06.035 |
摘要
复发或难治性急性淋巴细胞白血病(relapsed or refractory acute lymphoblastic leukemia，R/R ALL)的预后极其不佳，但随着嵌合抗原受体(chimeric antigen receptor，CAR)T细胞免疫疗法的引入患者预后已明显得到改善。CAR-T细胞免疫疗法独特的临床毒性及因免疫逃逸而导致的后期复发仍是当下医务工作者急需解决的问题。
关键词：
复发或难治性急性淋巴细胞白血病；嵌合抗原受体T细胞免疫疗法；免疫逃逸；临床毒性
Clinical application and progress in CAR-T cell immunotherapy
CorrespondingAuthor: ZHOU Jin Email: zhoujin1111@126.com
DOI: 10.3978/j.issn.2095-6959.2019.06.035
Abstract
The prognosis of relapsed or refractory acute lymphoblastic leukemia (R/R ALL) is extremely poor, but with the introduction of chimeric antigen receptor (CAR) T cell immunotherapy. The prognosis has improved significantly. The unique clinical toxicity of CAR-T cell immunotherapy and the late recurrence due to immune escape are still urgent problems for current medical workers.
Keywords：
relapsed or refractory acute lymphoblastic leukemia; chimeric antigen receptor-T cell immunotherapy; immune escape; clinical toxicity